79 Views | 33 Downloads
Dr. Kari B. Wisinski, UW Carbone Cancer Center, University of Wisconsin, Madison, 1111 Highland Avenue, WIMR 6033, Madison, WI 53705 USA. Email: kbwisinski@medicine.wisc.edu
Ticiana A. Leal: Conceptualization, resources, funding acquisition, investigation, methodology, supervision, writing‐original draft, writing‐review, and editing. Marina N. Sharifi: Data curation, formal analysis, investigation, visualization, methodology, writing‐original draft, writing‐review, and editing. Nancy Chan: Conceptualization, resources, methodology, writing‐review, and editing. Robert Wesolowski: Conceptualization, resources, methodology, writing‐review, and editing. Anita A. Turk: Data curation, formal analysis, visualization, methodology, writing‐review, and editing. Justine Y. Bruce: Resources, writing‐review, and editing. Ruth M. O'Regan: Resources, writing‐review, and editing. Jens Eickhoff: Resources, methodology, writing‐review, and editing. Lisa M. Barroilhet: Resources, writing‐review, and editing. Jyoti Malhotra: Conceptualization, resources, methodology, writing‐review, and editing. Janice Mehnert: Resources, writing‐review, and editing. Eugenia Girda: Resources, writing‐review, and editing. Elizabeth Wiley: Resources and investigation. Natalie Schmitz: Resources, formal analysis, investigation, visualization, methodology, writing‐review, and editing. Shannon Andrews: Resources, formal analysis, investigation, and methodology. Glenn Liu: Conceptualization, resources, methodology, writing‐review, and editing. Kari B. Wisinski: Conceptualization, resources, supervision, funding acquisition, methodology, writing‐original draft, writing‐review, and editing.
The authors thank the UW Carbone Cancer Center Cancer Therapy Discovery and Development Program (CTD2) for essential administrative and logistical support. The authors thank Cameron Scarlett, Ph.D. and Molly Pellitteri Hahn, M.S. (Analytical Instrumentation Center; School of Pharmacy; University of Wisconsin, Madison, WI) for their expertise in analyzing plasma samples for talazoparib concentration on the facility's Sciex 5500. The authors also thank Shannon Andrews, Ph.D. (Cancer Pharmacology Lab, University of Wisconsin Carbone Cancer Center) for the biomarker analysis of PAR, γH2AX, and RAD51. The biomarker analysis was completed under the expertise of Jennifer Schehr, Ph.D., Anupama Singh, Ph.D. (UWCCC Circulating Biomarker Core), and Lauren Nettenstrom, M.S. (UWCCC Flow Lab). We thank Sara Matthiesen, B.S. (Cancer Pharmacology Lab Sample Acquisition Services) for Biospecimen management.
Ticiana A. Leal: Consulting ‐ Boehringer‐Ingelheim, Jazz Pharmaceuticals, Genentech, Lilly; Advisory Boards ‐ AstraZeneca, EMD Serono, Merck, Boehringer‐Ingelheim, Blueprint, Bayer, Janssen, Mirati. Lisa M. Barroilhet: Advisory boards ‐ Clovis, Astrazeneca, Kiayatec. Kari B. Wisinski: Research support ‐ Pfizer, Context, Novartis; Scientific Advisory boards ‐ Eisai, AstraZeneca, Pfizer, Sanofi, Daiichi Sankyo, Novartis. The other authors declare no potential conflict of interest.
Supported by UW Comprehensive Cancer Center Support Grant (CCSG) (P30CA014520) and The John Hopkins Translational Science Team and Consortium for ETCTN Studies (UM1CA186691).
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.